ArticleBMJ open diabetes research & care2026
Zero Dollar Drug Copay program improves antidiabetic medication adherence and medication use patterns among Blue Cross and Blue Shield of Louisiana members with diabetes in Louisiana.
Article in BMJ open diabetes research & care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectiveBlue Cross and Blue Shield of Louisiana (BCBSLA) launched a zero-dollar co-pay (ZDC) pharmacy benefit on July 1, 2020, to reduce cost-related barriers to diabetes medications. This study evaluated the program's effect on antidiabetic medication adherence and use patterns. RESEARCH DESIGN AND
methodsWe conducted a retrospective cohort study using BCBSLA medical and pharmacy claims from 2019-2021. The study included 7,603 continuously enrolled members with diabetes: 3,045 fully insured members with ZDC coverage (ZDC group) and 4,558 administrative-services-only members without ZDC coverage (control group). Follow-up was July 1, 2020, to December 31, 2021. Outcomes included monthly proportion of days covered (PDC), drug counts, and monthly medication use. We applied propensity score odds weights and estimated weighted difference-in-differences models with individual and time fixed effects, adjusting for demographics, comorbidities, healthcare utilization, and spending. Subgroup analyses examined pre-ZDC users, pre-ZDC non-users, and complex users.
resultsMean age was 48.8 (SD 12.5) years in the ZDC group and 52.9 (SD 11.3) years in controls; 57.4% and 55.6% were female, respectively. The ZDC program increased PDC by 4.4 percentage points (p<0.001), monthly medication use by 6.2 percentage points (p<0.001), and drug counts by 0.090 (p<0.001). For ZDC-eligible medications, increases were 5.4 percentage points for PDC, 7.6 percentage points for monthly use, and 0.074 for drug counts (all p<0.001). Improvements were observed among pre-ZDC users and complex users, but not among pre-ZDC non-users.
conclusionA zero-dollar co-pay pharmacy benefit improved antidiabetic medication adherence and increased medication use among BCBSLA members with diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.